Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

  • ID:PD038051
  • July 2019
  • GIR (Global Info Research)
                          

The Global Benign Prostatic Hyperplasia (BPH) Drugs Market Report is equipped with market data from 2014 to 2024. The report gives a market overview covering key drivers and risks factors. The report is bifurcated by top global manufactures mentioning sales, revenue and prices as applicable. It also evaluates the competitive scenario of the leading players. The report expands to cover regional market data along with type and application. The report forecasts sales and revenue from 2019 to 2024. The detailed sales channel is also covered in the study.

Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.

Scope of the Report:
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market.  Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.

The worldwide market for Benign Prostatic Hyperplasia (BPH) Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019.

This report focuses on the Benign Prostatic Hyperplasia (BPH) Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers

  •     Astellas Pharma
  •     Eli Lilly
  •     GlaxoSmithKline
  •     Sanofi
  •     ADC Therapeutics
  •     Bayer HealthCare
  •     Bristol-Myers Squibb
  •     Valeant Pharmaceuticals
  •     Endo Pharmaceuticals
  •     Foresee Pharmaceuticals

Market Segment by Regions, regional analysis covers
  •     North America (United States, Canada and Mexico)
  •     Europe (Germany, France, UK, Russia and Italy)
  •     Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
  •     South America (Brazil, Argentina, Colombia etc.)
  •     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
  •     Alpha-Blocker
  •     Phosphodiesterase Type-5 Inhibitors
  •     5-Alpha-Reductase Inhibitors

Market Segment by Applications, can be divided into
  •     Men
  •     Women

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Benign Prostatic Hyperplasia (BPH) Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, with price, sales, revenue and global market share of Benign Prostatic Hyperplasia (BPH) Drugs in 2017 and 2018.
Chapter 3, the Benign Prostatic Hyperplasia (BPH) Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Benign Prostatic Hyperplasia (BPH) Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Benign Prostatic Hyperplasia (BPH) Drugs market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Benign Prostatic Hyperplasia (BPH) Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Benign Prostatic Hyperplasia (BPH) Drugs Introduction
    1.2 Market Analysis by Type
        1.2.1 Alpha-Blocker
        1.2.2 Phosphodiesterase Type-5 Inhibitors
        1.2.3 5-Alpha-Reductase Inhibitors
    1.3 Market Analysis by Applications
        1.3.1 Men
        1.3.2 Women
    1.4 Market Analysis by Regions
        1.4.1 North America (United States, Canada and Mexico)
            1.4.1.1 United States Market States and Outlook (2014-2024)
            1.4.1.2 Canada Market States and Outlook (2014-2024)
            1.4.1.3 Mexico Market States and Outlook (2014-2024)
        1.4.2 Europe (Germany, France, UK, Russia and Italy)
            1.4.2.1 Germany Market States and Outlook (2014-2024)
            1.4.2.2 France Market States and Outlook (2014-2024)
            1.4.2.3 UK Market States and Outlook (2014-2024)
            1.4.2.4 Russia Market States and Outlook (2014-2024)
            1.4.2.5 Italy Market States and Outlook (2014-2024)
        1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
            1.4.3.1 China Market States and Outlook (2014-2024)
            1.4.3.2 Japan Market States and Outlook (2014-2024)
            1.4.3.3 Korea Market States and Outlook (2014-2024)
            1.4.3.4 India Market States and Outlook (2014-2024)
            1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
        1.4.4 South America, Middle East and Africa
            1.4.4.1 Brazil Market States and Outlook (2014-2024)
            1.4.4.2 Egypt Market States and Outlook (2014-2024)
            1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
            1.4.4.4 South Africa Market States and Outlook (2014-2024)
            1.4.4.5 Turkey Market States and Outlook (2014-2024)
    1.5 Market Dynamics
        1.5.1 Market Opportunities
        1.5.2 Market Risk
        1.5.3 Market Driving Force
2 Manufacturers Profiles
    2.1 Astellas Pharma
        2.1.1 Business Overview
        2.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
            2.1.2.1 Product A
            2.1.2.2 Product B
        2.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    2.2 Eli Lilly
        2.2.1 Business Overview
        2.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
            2.2.2.1 Product A
            2.2.2.2 Product B
        2.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    2.3 GlaxoSmithKline
        2.3.1 Business Overview
        2.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
            2.3.2.1 Product A
            2.3.2.2 Product B
        2.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    2.4 Sanofi
        2.4.1 Business Overview
        2.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
            2.4.2.1 Product A
            2.4.2.2 Product B
        2.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    2.5 ADC Therapeutics
        2.5.1 Business Overview
        2.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
            2.5.2.1 Product A
            2.5.2.2 Product B
        2.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    2.6 Bayer HealthCare
        2.6.1 Business Overview
        2.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
            2.6.2.1 Product A
            2.6.2.2 Product B
        2.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    2.7 Bristol-Myers Squibb
        2.7.1 Business Overview
        2.7.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
            2.7.2.1 Product A
            2.7.2.2 Product B
        2.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    2.8 Valeant Pharmaceuticals
        2.8.1 Business Overview
        2.8.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
            2.8.2.1 Product A
            2.8.2.2 Product B
        2.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    2.9 Endo Pharmaceuticals
        2.9.1 Business Overview
        2.9.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
            2.9.2.1 Product A
            2.9.2.2 Product B
        2.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    2.10 Foresee Pharmaceuticals
        2.10.1 Business Overview
        2.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
            2.10.2.1 Product A
            2.10.2.2 Product B
        2.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
    3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Manufacturer (2017-2018)
    3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Manufacturer (2017-2018)
    3.3 Market Concentration Rate
        3.3.1 Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2018
        3.3.2 Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2018
    3.4 Market Competition Trend
4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis by Regions
    4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Regions
        4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Regions (2014-2019)
        4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Regions (2014-2019)
    4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs  Sales and Growth Rate (2014-2019)
    4.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs  Sales and Growth Rate (2014-2019)
    4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs  Sales and Growth Rate (2014-2019)
    4.5 South America Benign Prostatic Hyperplasia (BPH) Drugs  Sales and Growth Rate (2014-2019)
    4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs  Sales and Growth Rate (2014-2019)
5 North America Benign Prostatic Hyperplasia (BPH) Drugs by Country
    5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Country
        5.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Country (2014-2019)
        5.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Country (2014-2019)
    5.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    5.3 Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    5.4 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
6 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Country
    6.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Country
        6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Country (2014-2019)
        6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Country (2014-2019)
    6.2 Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    6.3 UK Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    6.4 France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    6.5 Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    6.6 Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
7 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs by Country
    7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Country
        7.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Country (2014-2019)
        7.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Country (2014-2019)
    7.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    7.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    7.4 Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    7.5 India Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    7.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
8 South America Benign Prostatic Hyperplasia (BPH) Drugs by Country
    8.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Country
        8.1.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Country (2014-2019)
        8.1.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Country (2014-2019)
    8.2 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    8.3 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    8.4 Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
9 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs by Countries
    9.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Country
        9.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Country (2014-2019)
        9.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Country (2014-2019)
    9.2 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    9.3 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    9.4 Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    9.5 Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
    9.6 South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2019)
10 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment by Type
    10.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2014-2019)
        10.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type (2014-2019)
        10.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2014-2019)
    10.2 Alpha-Blocker Sales Growth and Price
        10.2.1 Global Alpha-Blocker Sales Growth (2014-2019)
        10.2.2 Global Alpha-Blocker Price (2014-2019)
    10.3 Phosphodiesterase Type-5 Inhibitors Sales Growth and Price
        10.3.1 Global Phosphodiesterase Type-5 Inhibitors Sales Growth (2014-2019)
        10.3.2 Global Phosphodiesterase Type-5 Inhibitors Price (2014-2019)
    10.4 5-Alpha-Reductase Inhibitors Sales Growth and Price
        10.4.1 Global 5-Alpha-Reductase Inhibitors Sales Growth (2014-2019)
        10.4.2 Global 5-Alpha-Reductase Inhibitors Price (2014-2019)
11 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment by Application
    11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2014-2019)
    11.2 Men Sales Growth (2014-2019)
    11.3 Women Sales Growth (2014-2019)
12 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2019-2024)
    12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2019-2024)
    12.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Regions (2019-2024)
        12.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2019-2024)
        12.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2019-2024)
        12.2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2019-2024)
        12.2.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2019-2024)
        12.2.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2019-2024)
    12.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Type (2019-2024)
        12.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2019-2024)
        12.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Type (2019-2024)
    12.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Application (2019-2024)
        12.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2019-2024)
        12.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
    13.1 Sales Channel
        13.1.1 Direct Marketing
        13.1.2 Indirect Marketing
        13.1.3 Marketing Channel Future Trend
    13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
    15.1 Methodology
    15.2 Data Source

Related Categories
Pharmaceuticals
Related Reports
Global Tigecycline Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027

The report on the Global Tigecycline Market gives an estimation of the development of the market based on historical studies and also provides forecasts  read more..


Global Risperidone Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

The Global Risperidone Market Report is equipped with market data from 2015 to 2025. The report gives a market overview covering key drivers and risks  read more..


Global Caffeine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027

The report on the Global Caffeine Market gives an estimation of the development of the market based on historical studies and also provides forecasts on  read more..


Global Rabies Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027

The report on the Global Rabies Vaccine Market gives an estimation of the development of the market based on historical studies and also provides  read more..


Global Radiopharmaceuticals Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027

The report on the Global Radiopharmaceuticals Market gives an estimation of the development of the market based on historical studies and also provides  read more..


Global Neurorehabilitation System Market Research Report

The report on the Global Neurorehabilitation System Market gives an estimation of the development of the market based on historical studies and also  read more..


Global Molecular Biology Kits And Reagents Market Research Report

The report on the Global Molecular Biology Kits And Reagents Market gives an estimation of the development of the market based on historical studies and  read more..


Global High Acuity Care Information Systems Market Research Report

The report on the Global High Acuity Care Information Systems Market gives an estimation of the development of the market based on historical studies and  read more..


Global Regenerative Medicine Market Research Report

The global regenerative medicine market was estimated to be at ~$4.5 billion in 2013.   A number of factors such as increasing bone related  read more..


Global Skin Cancer Diagnostics Market Research Report

The report on the Global Skin Cancer Diagnostics Market gives an estimation of the development of the market based on historical studies and also  read more..